CompuMed Integrates the Techcyte Digital Pathology Reviewing Platform to Help Increase Transplanted Organs

Rhea-AI Summary

Techcyte and CompuMed collaborate to enhance digital manual review of organs for transplantation.

Positive

• Techcyte and CompuMed's collaboration aims to reshape the landscape of organ transplantation, allowing quicker, more accurate decisions, increasing the organs transplanted, and ultimately, saving more lives.

Negative

• Reading biopsies from deceased donors is complex, and many hospitals lack the staffing and donor volumes to provide consistent and accurate data for surgeons and transplant teams to make informed decisions.

Techcyte, the world leader in AI-based cellular digital diagnostics, is pleased to announce a collaboration with CompuMed to enhance the digital manual review of available livers and kidneys for organ transplantation. As a leader in diagnostic telemedicine, CompuMed prides itself on providing remote pathology reads anywhere, at any time. To further its mission and better serve its partners in the donation and transplantation community, CompuMed has adopted the Techcyte digital reviewing platform, a feature of Techcyte's clinical pathology AI platform.

Organ transplantation remains the gold standard for managing end-stage organ failure, but the demand for transplantable organs significantly outweighs the supply. According to OPTN/SRTR data, in 2021 nearly 25% of recovered organs are not utilized for transplantation, with this issue worsening over time.

A leading cause of the nonuse of viable organs is inconsistent biopsy reports. Reading biopsies from deceased donors is complex, and many hospitals lack the staffing and donor volumes to provide consistent and accurate data for surgeons and transplant teams to make informed decisions. CompuMed board-certified liver and kidney pathologists will use the Techcyte digital reviewing platform to conduct improved specialized digital reviews of frozen biopsies remotely to provide more standardized information so that more organs are made available for transplant.

In crucial time-sensitive settings like operating rooms where every second counts, organ procurement teams will digitize and upload organ tissue slides onto CompuMed's secure cloud network. Available round-the-clock, CompuMed's sub-specialist pathologists will review these slides on Techcyte's platform, tagging key biopsy parameters, directly linking them to digital images, and sharing the documented images in their reports. This streamlined process will allow transplant surgeons to swiftly validate biopsy findings, bolstering their decision-making confidence and thereby enhancing the prospects of saving the life of waiting patients.

Ben Cahoon, CEO of Techcyte, remarks, "Our partnership with CompuMed showcases Techcyte's commitment to leveraging technology to advance digital diagnostics, thereby contributing positively to the transplantation community's lifesaving endeavors."

"CompuMed's collaboration with Techcyte signifies a pivotal moment in the field of transplantation, offering the promise of better organ graft evaluation and higher success rates," says Lee Keddie, CEO of CompuMed. "By leveraging technology to enhance the assessment of transplant organs, this collaboration aims to reshape the landscape of organ transplantation, allowing quicker, more accurate decisions, increasing the organs transplanted, and ultimately, saving more lives."

###

About Techcyte

Techcyte, Inc. was founded in 2013 in Orem, Utah, and is the world leader in AI-based cellular digital diagnostics. Techcyte's Clinical Pathology AI Platform uses deep machine learning to perform automated analysis of whole slide microscopy images, revolutionizing digital diagnostics for human, animal, and environmental clinics and labs.

Techcyte's clinical pathology platform is for Research Use Only in the United States.

About CompuMed

CompuMed is the go-to provider of clinical organ analysis, offering rapid diagnostic reads by industry-best expert physicians through a seamless platform and process. With a commitment to service, innovation, and excellence, CompuMed is dedicated to helping save more lives. CompuMed, Inc. (OTCPink: CMPD) Diagnostic Telemedicine services provide our customers with the highest level of clinical care. Its telecardiology, telepathology, teleradiology and telepulmonology offerings provide real-time access to U.S. board-certified specialists through cloud-based technology 24/7/365.

View source version on accesswire.com:
https://www.accesswire.com/795738/compumed-integrates-the-techcyte-digital-pathology-reviewing-platform-to-help-increase-transplanted-organs

FAQ

What is the collaboration between Techcyte and CompuMed about?

Techcyte and CompuMed are collaborating to enhance the digital manual review of available livers and kidneys for organ transplantation.

What is the goal of the collaboration?

The goal of the collaboration is to provide more standardized information from improved specialized digital reviews of frozen biopsies, so that more organs are made available for transplant.

Why is reading biopsies from deceased donors complex?

Reading biopsies from deceased donors is complex due to the lack of consistent and accurate data, as many hospitals lack the staffing and donor volumes to provide this information.

How will the collaboration benefit transplant surgeons?

The collaboration will allow transplant surgeons to swiftly validate biopsy findings, enhancing their decision-making confidence and increasing the prospects of saving the life of waiting patients.

What is the potential impact of the collaboration?

The collaboration aims to reshape the landscape of organ transplantation by offering the promise of better organ graft evaluation and higher success rates.